文献速递糖尿病

闭环胰岛素治疗用于接受胰岛素泵治疗的2型糖尿病患者:一项为期12周的多中心、开放标签、随机、对照、交叉试验

Closed-Loop Insulin Therapy for People With Type 2 Diabetes Treated With an Insulin Pump: A 12-Week Multicenter, Open-Label Randomized, Controlled, Crossover Trial.
PubMed 文献 · Diabetes Care · 2024-01-01

该多中心随机交叉试验在17例既往使用持续皮下胰岛素输注(CSII)的2型糖尿病患者中比较混合闭环设备(DBLG1)与CSII+持续葡萄糖监测(CGM)的血糖控制效果。主要终点为目标范围内时间(TIR)在闭环条件下升至76.0%,而CSII+CGM条件下为61.0%,平均差异15.0个百分点(P<0.001)。结论认为闭环治疗对2型糖尿病患者的血糖控制优于CSII+CGM。

要点

  • 闭环治疗期间TIR为76.0%,CSII+CGM期间为61.0%,平均差异15.0个百分点(P<0.001)。
  • 次要终点显示闭环治疗降低高于范围时间、葡萄糖管理指标和血糖变异性,并增加每日胰岛素剂量。
  • 活动记录仪睡眠分析显示闭环治疗期间睡眠碎片化改善。

核心结论

  • 在既往接受CSII治疗的2型糖尿病患者中,闭环治疗对血糖控制的改善优于CSII+CGM。

研究设计与样本

  • 随机、对照、交叉、两阶段、开放标签、多中心研究,于2022年8月至2023年7月开展,共纳入17例受试者(9例先接受6周CSII+CGM,8例先接受6周闭环治疗)。
  • 主要终点为目标范围内时间(TIR:70-180 mg/dL),次要结局包括其他CGM血糖指标、体力活动和睡眠(使用1周活动记录仪客观测量)。
  • 数据采用改良意向性治疗(modified intention-to-treat)方法分析。

主要发现

  • 平均年龄63岁(SD 9),女性占35%,入组时平均HbA1c为7.9%(SD 0.9)。
  • 闭环条件下TIR增至76.0%(四分位距69.0-84.0),而CSII+CGM条件下为61.0%(四分位距55.0-70.0);平均差异为15.0个百分点(四分位距8.0-22.0;P < 0.001)。
  • 次要终点分析显示高于范围时间、葡萄糖管理指标和血糖变异性降低,每日胰岛素剂量增加。
  • 活动记录仪睡眠分析显示闭环治疗期间睡眠碎片化改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Continuous glucose monitoring (CGM) combined with continuous subcutaneous insulin infusion (CSII) achieves better glycemic control than multi-injection therapy in people with type 2 diabetes. The effectiveness of closed-loop therapy needs to be further evaluated in this population. RESEARCH DESIGN AND METHODS: The study objective was to measure the impact of a hybrid closed-loop device (DBLG1) compared with CSII + CGM on glycemic control in people with type 2 diabetes previously treated with CSII. The randomized, controlled, crossover, two-period, open-label, and multicenter study was conducted from August 2022 to July 2023 in 17 individuals (9 to receive 6 weeks of CSII + CGM first and 8 to receive 6 weeks of closed-loop therapy first). The primary end point was the percentage time in range (TIR: 70-180 mg/dL). Secondary outcomes were other CGM-glucose metrics, physical activity, and sleep objectively measured using 1-week actimetry. RESULTS: Data were analyzed using a modified intention-to-treat approach. Mean age was 63 (SD 9) years and 35% were women. Mean HbA1c at inclusion was 7.9% (SD 0.9). TIR increased to 76.0% (interquartile range 69.0-84.0) during the closed-loop condition vs. 61.0% (interquartile range 55.0-70.0) during the CSII + CGM condition; mean difference was 15.0 percentage points (interquartile range 8.0-22.0; P < 0.001). Analyses of secondary end points showed a decrease in time above range, in glucose management indicator, in glucose variability, and an increase in daily insulin dose. Actimetric sleep analysis showed an improvement in sleep fragmentation during closed-loop treatment. CONCLUSIONS: Closed-loop therapy improved glycemic control more than did CSII + CGM in people with type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Borel AL, Lablanche S, Waterlot C, et al. Closed-Loop Insulin Therapy for People With Type 2 Diabetes Treated With an Insulin Pump: A 12-Week Multicenter, Open-Label Randomized, Controlled, Crossover Trial. Diabetes Care. 2024. PMID: 39106206. doi:10.2337/dc24-0623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。